

KEPUSTAKAAN

1. American Cancer Society. How many women get ovarian cancer? cited 2004, February 22, available at www.cancer.org/docroot/CRI/content/CRI
2. Laurvick CL, Semmens JB. Ovarian Cancer in Western Australia 1982-1998: A population – based review of the trends and outcomes, Proceedings symposium on Health Data Linkage. cited 2003, Desember, available at www.publichealth.gov.au
3. Sapardan, Tumor ovarium, Naskah lengkap KOGI IV, 1979, Jogjakarta, hal 433.
4. Kris A, Keganasan ovarian di RS Sardjito tahun 2000 – 2002. Referat. Bagian Obstetri Ginekologi FK UGM/ RS. Sardjito, Jogjakarta.
5. Griwies DA, Economy KE, *Primary prevention of Gynecology Cancer in current Development*, Mosby – Year Book. Inc, 1995, p 227 – 35.
6. Disaia PJ, Creasman WF. *The adnexal mass and early ovarian cancer in clinical Gynecology Oncology*, 5th ed, 1997, p 259-374.
7. Berek JS, FU YS, Hacker NF, Ovarian cancer in Novaks Gynecology, 12th ed. William & Wilkins, Pennysilvania, 1996, p 1155-230.
8. Andrijono, Sinopsis Kanker Ginekologi, Sub Bagian Onkologi, Bagian Onkologi dan Ginekologi, 2003, FKUI, Jakarta.
9. Ozols RF, Garvin AJ, Costa J, Simon RM, Young RC. Advanced ovarian cancer: correlation of histologic grade with response to therapy and survival. *Cancer*, 1980: 45: 572-81.

10. Prasad GR, Dalal AV, Tongaonkar HB, Clatterjee S, Kamet MR, Impact of Cisplatin based chemotherapy on advanced ovarian cancer, Journal of postgraduate medicine, 1995, vol 41, issue 4, p 95-8
11. Amadori, D Sansoni E, Amadori A, Ovarian Cancer: *Natural History and Metastatic pattern*, Frontiers in Bioscience, January 1, 1996, p56-9.
12. Van de Velde CJH. Bosman FT, Wagener DJ. Onkologi edisi 5, Panitia Kanker RSUP Dr. Sardjito, 1999, Jogjakarta, hal 494-507.
13. Hellman K, Carter SK. Fundamentals of cancer chemotherapy. Mc. Graw-Hill Book company, 1987
14. Sukardja IGD. Onkologi Klinik edisi 2, Airlangga university press, 2000
15. Polsdorfer R. Chemotherapy for ovarian cancer, available from <http://healthinfo.healthgate.com/getcontent.aspx?takekey=b6097602> cited 07/01/05
16. Oncology channel. *Ovarian cancer chemoterapi*, cited December 12, 2004, available at www.oncologychannel.com
17. Nath W. Ovarian tumor marker: cancer antigen 125. available from www.thedoctordocor.com/labtest/ca-125.html, cited 13/9/2005
18. CA 125 blood test for ovarian cancer. available from www.focusoncancer.com/script/main/Art.asp?li=MNI&articleKey=8099
19. Young, R.C. *Gynecology malignancy: ovarian cancer*, cited Decemder 2004, available www.harrisononline.com,
20. Welander CE, What do CA 125 and other antigens tell us about ovarian cancer biology? Acta Obstet Gynecol Scand Suppl, 1992; 155: 85-93

21. Partridge EE, Barnes MN. Epithelial ovarian cancer: prevention. Diagnosis and treatment, *Cancer J. Clin*, 1999; 49:297-320
22. Holtz A. Special report: Tumor Marker CA 125, Exclusive Sapient Health Network. Report, 1997, available from www.nasw.org/users/holtza/SHNCA125.html
23. Grounlund B, Hagdall C, Hilden J, Engelholm SA, Hagdall EVS, Hansen HH. Should CA 125 respon criteria be preferred to respon evaluation criteria in solid tumor (RECIST) for prognostication during second line chemotherapy of ovarian carcinoma? *Journal of Clinical Oncology*, 2004, vol 22: no 20.
24. Gordon, Rustin JS, Robert C, Bast Jr, Gary J, Kellof J, Barrett C, Carter SK, Nissen PD, Sigman CC, Parkinson DR, Ruddon RW. Use of CA 125 in clinical trial evaluation of new therapeutic drug for ovarian cancer, *Clinical Cancer Research* June 1, 2004, vol 10, p 3926.
25. Siswosudarmo HR. *Obstetri Fisiologi*. Andi Offset, Jogjakarta, 1992
26. Sastroasmoro, S dan Ismael, S, *Dasar-dasar metodologi penelitian klinis edisi II*, Sagung Seto, Jakarta, 2002
27. Benedet, JL. Ngan, HYS. Hacker, NF. Staging classifications and clinical practice guidelines of gynaecologic cancers. *International Journal of gynecology and Obstetrics* 70: 2000; 207-312
28. Bast RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshins A, Menon U, Jacobs I, LUK, New tumor markers: CA 125 and beyond. *Int J Gynecol Cancer* 2005, 15 (Suppl.3), 274-281.

29. Duffy MJ, Bonfrer JM, Kulpas J, Rustin GJS, Soletormos G, Torre GC, Tuxen MK, Zwirner M. CA 125 in ovarian cancer: European Group on tumor Marker guidelines for clinical use. *Int J Gynecol Cancer* 2005, 15, 679-691
30. Balducci, L, Beghe, C, Pharmacology of chemotherapy in older cancer patient. *Cancer Center Journal* vol 6: no 5 available at www.Moffitt.usf.edu/pubs/article4.html
31. Mangioni C, Bonazzi C, Peccatori F, Pellogrino A, Chiari S, Pittelli MR. Non dysgerminous ovarian germ cell tumor: conservative surgery and fertility. *Int J Gynecology Cancer*, 1993;3: Suppl 1: 33.
32. Nuranna L, Aziz MF, Kampono N, SjamsuddinS, Andrijono, Penatalaksanaan neoplasma ovarium suspek ganas pada usia muda. KOGI IX, Jakarta, 1993
33. Makar AP, Kristensen GB, Kaern J, Borner OP, Abeler VM, Trope, GG. Prognostic value of pre and postoperative serum CA 125 level in ovarian cancer: new aspect and multivariate analysis, *Obstet Gynecol*, 1992, June: 79:1002-10.
34. Vermorken JB. *Gynecologic cancer*, Gynecological cancer, 13 (suppl 2) 2003, p 178-84.
35. Kehoe S. Surgery in gynaecological cancer available at <http://medweb.bham.ac.uk/divisions/reprochildhealth/obgyn/Surgery.htm>
36. Brockbank EC, Ind TEJ, Barton, DPI, Shepherd JH, Gore ME, A'Hern R, Bridges JE. Preoperative predictors of suboptimal primary surgical cytoreduction on women with clinical evidence of advanced primary epithelial ovarian cancer. *Int J Gynecol Cancer* 2004, 14, 42-50.